公开(公告)号：US20150018373A1

公开(公告)日：2015-01-15

申请号：US14325564

申请日：2014-07-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Hideyuki IGAWA ,  Masashi TAKAHASHI ,  Keiko KAKEGAWA ,  Minoru IKOMA ,  Jumpei AIDA

IPC: C07D401/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/14 ,  C07D409/14

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: Provided is a compound having a melanin-concentrating hormone receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of obesity and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 提供具有黑色素浓集激素受体拮抗作用的化合物，并且可用作预防或治疗肥胖症等的药剂。 由式（I）表示的化合物或其盐，其中每个符号如说明书中所定义。

公开(公告)号：US20220274982A1

公开(公告)日：2022-09-01

申请号：US17630840

申请日：2020-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Yuta TANAKA ,  Fumiaki KIKUCHI ,  Takeshi YAMAMOTO ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Yasufumi WADA ,  Keiko KAKEGAWA ,  Takahito KASAHARA ,  Tomohiro OHASHI ,  Junsi WANG ,  Zenichi IKEDA ,  Florian PUENNER ,  Masaki SETO ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D471/04

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20190135799A1

公开(公告)日：2019-05-09

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Takeshi YASUI ,  Keiko KAKEGAWA ,  Zenichi IKEDA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Akinori TOITA ,  Takuto KOJIMA ,  Yasutomi ASANO ,  Ayumu SATO ,  Hironobu MAEZAKI ,  Shinobu SASAKI ,  Hironori KOKUBO ,  Misaki HOMMA ,  Minoru SASAKI ,  Yasuhiro IMAEDA

IPC: C07D413/14 ,  C07D471/04 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20170349605A1

公开(公告)日：2017-12-07

申请号：US15539607

申请日：2015-12-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru SASAKI ,  Fumiaki KIKUCHI ,  Zenichi IKEDA ,  Keiko KAKEGAWA ,  Yoichi NISHIKAWA ,  Shigekazu SASAKI ,  Koichiro FUKUDA ,  Kazuaki TAKAMI ,  Yoshihiro BANNO ,  Masahiro KAMAURA

IPC: C07D495/04 ,  C07D491/044 ,  C07D413/06 ,  C07D323/00 ,  C07D313/00 ,  C07D321/12 ,  C07D321/00 ,  C07D313/20 ,  C07D493/04 ,  C07D405/06

CPC classification number: C07D495/04 ,  A61K31/365 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/662 ,  C07D313/00 ,  C07D313/20 ,  C07D321/00 ,  C07D321/12 ,  C07D323/00 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D491/044 ,  C07D493/04 ,  C07F9/655

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].